Acne And Related Disorders is an indication for drug development with over 60 pipeline drugs currently active. According to GlobalData, preregistered drugs for Acne And Related Disorders have a 83.33% likelihood of approval (LoA) indication benchmark. GlobalData’s report assesses how phase transition success rate (PTSR) and likelihood of approval (LoA) scores for pipeline drugs in Acne And Related Disorders compared to historical benchmarks. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Acne And Related Disorders overview

Acne and related disorders encompass a range of skin conditions primarily affecting the pilosebaceous unit, characterized by the formation of pimples, blackheads, whiteheads, and inflammation. These conditions arise due to a combination of factors including excess oil production, clogged pores, bacteria, hormonal fluctuations, and genetic predisposition. Acne vulgaris represents the most common form, occurring primarily during adolescence but can persist into adulthood. Other variations like cystic acne, nodular acne, or acne rosacea may present with more severe symptoms and inflammation. Treatment approaches include topical treatments, oral medications, lifestyle modifications, and, in severe cases, procedures like chemical peels or laser therapy, aiming to manage symptoms and prevent scarring while improving skin appearance and self-confidence.

For a complete picture of PTSR and LoA scores for drugs in Acne And Related Disorders, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article. 

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.